Avita Medical (AVMXY) 2.3101 $AVMXY
United States Food and Drug Administration Grants an Investigational Device Exemption for Compassionate Use of ReCell
Marketwire - Thu Apr 10, 8:31AM CDT
Avita Medical Limited (ASX: AVH), (OTCQX: AVMXY)
ReCell Containing Ambient-Stored Enzyme Launched in United Kingdom and Europe
Marketwire - Tue Apr 08, 12:10PM CDT
Regenerative medicine company Avita Medical Limited "Avita Medical" (ASX: AVH) (OTCQX: AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell(R) 'Spray-on Skin(R)' that no longer requires refrigeration. This greatly improves the commercial and practical benefits to clinicians.
Avita Medical: Update to Shareholders
Marketwire - Wed Dec 11, 8:02AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Avita Medical Announces Completion of Enrollment in ReCell(R) Trial for Vitiligo
Marketwire - Wed Aug 21, 7:01AM CDT
Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY)
Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
Marketwire - Mon Aug 05, 7:00AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has a regenerative medicine device product called ReCell(R) Spray-On Skin(R) (autologous cell suspension), a treatment for severe skin defects, burns, scalds, scars, vitiligo (discoloration of the skin when melanin is lost), acne scarring and what I call the holy grail of indications, chronic wounds. I like this product because it makes sense for burns and scalds, especially in children. It's a difficult story to communicate -- the pictures at the company's website are worth a thousand words. Avita's ReCell product is fantastic because all that is needed to generate the suspension is skin from a donor site about the size of a postage stamp, instead of a huge harvest that creates another large wound, and two painful sites that need to heal. With ReCell, a skin biopsy is put in the ReCell kit, which separates and isolates the patient's skin cells through an easy-to-follow, six-step process. The cells can then be sprayed onto the wound and a new layer of healthy skin grows. It's approved in Europe... in the U.S., ReCell is essentially in phase 3, and we'll get data from that trial next year. Then Avita will file for approval, and ReCell should be on the U.S. market in 2015. From a burns and scalds standpoint, ReCell is going to dominate the market. From an acne scarring or vitiligo standpoint, I think it can capture significant market share."
Avita Medical Enrolls First Patients in ReCell(R) Trial for Chronic Leg Ulcers
Marketwire - Thu Aug 01, 8:30AM CDT
Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY)
Zacks Investment Research Initiates Coverage on Avita Medical (OTCQX:AVMXY) (ASX:AVH) with a Buy Recommendation - Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Wed Jun 26, 4:03PM CDT
Vancouver, British Columbia, June 26, 2013 - Zacks Investment Research has initiated coverage on Avita Medical (OTCQX:AVMXY) (ASX:AVH). Analyst Jason Napadano gives the company a buy rating and a $4.00 US price target, a premium of 95% over the $2.05 price the day the report was issued.
Avita Medical Analyst Coverage Initiated by Zacks
Marketwire - Wed Jun 19, 3:37PM CDT
Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) is pleased to announce that Zacks Investment Research, Inc (zacks.com), based in Chicago, IL, USA, has initiated coverage.
Granted Japanese Patent Expands Commercial Rights for ReCell(R) Spray-On Skin(R) Technology in Asia
Marketwire - Wed Apr 10, 8:30AM CDT
Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY) is pleased to announce that it has secured the grant of Japanese Patent No. 5214085 "Cell Suspension Preparation Technique and Device" by the Japanese Patent Office.
Avita Medical Skin Regeneration Symposium Attracts Top European Surgeons
Marketwire - Thu Mar 28, 8:30AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
M2 - Thu Feb 28, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/9qnbnv/global) has announced the addition of iCD Research's new report "Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry" to their offering. "Global Pharmaceutical Survey 2013-2014: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry is a new report that analyzes how pharmaceutical industry companies' media spend, marketing and sales strategies and practices, and business planning are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report provides the current size of the marketing and advertising budgets of global pharmaceutical industry suppliers and how spending by global pharmaceutical industry suppliers will change, providing an insight into global marketing behaviour. In addition, the report identifies future growt
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
M2 - Tue Feb 26, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/v5d4c7/global) has announced the addition of iCD Research's new report "Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" to their offering. Global Pharmaceutical Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry is a new report that analyzes how pharmaceutical industry companies' procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report gives access to category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procuremen
Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now
Marketwire - Thu Feb 14, 8:00AM CST
William Dolphin, Ph.D., the CEO of regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), was interviewed by SNNLive last week. Dr. Dolphin provides an update on Avita's flagship product, ReCell(R) Spray-On Skin(R). Based on Avita's proprietary technology, ReCell is designed to provide a rapid, safe and effective point of care treatment for regrowing skin tissue that has been damaged due to trauma, disease, or senescence.
Avita Medical Completes ISO Quality Audit, CE Mark Recertification
Marketwire - Wed Feb 13, 12:23PM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Avita Medical Appoints Dr. Michael S. Perry to Board of Directors
Marketwire - Wed Feb 06, 11:21AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
United States Food and Drug Administration Grants an Investigational Device Exemption for Compassionate Use of ReCell
Marketwire - Thu Apr 10, 8:31AM CDT
Avita Medical Limited (ASX: AVH), (OTCQX: AVMXY)
ReCell Containing Ambient-Stored Enzyme Launched in United Kingdom and Europe
Marketwire - Tue Apr 08, 12:10PM CDT
Regenerative medicine company Avita Medical Limited "Avita Medical" (ASX: AVH) (OTCQX: AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell(R) 'Spray-on Skin(R)' that no longer requires refrigeration. This greatly improves the commercial and practical benefits to clinicians.
Avita Medical: Update to Shareholders
Marketwire - Wed Dec 11, 8:02AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Avita Medical Announces Completion of Enrollment in ReCell(R) Trial for Vitiligo
Marketwire - Wed Aug 21, 7:01AM CDT
Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY)
Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
Marketwire - Mon Aug 05, 7:00AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has a regenerative medicine device product called ReCell(R) Spray-On Skin(R) (autologous cell suspension), a treatment for severe skin defects, burns, scalds, scars, vitiligo (discoloration of the skin when melanin is lost), acne scarring and what I call the holy grail of indications, chronic wounds. I like this product because it makes sense for burns and scalds, especially in children. It's a difficult story to communicate -- the pictures at the company's website are worth a thousand words. Avita's ReCell product is fantastic because all that is needed to generate the suspension is skin from a donor site about the size of a postage stamp, instead of a huge harvest that creates another large wound, and two painful sites that need to heal. With ReCell, a skin biopsy is put in the ReCell kit, which separates and isolates the patient's skin cells through an easy-to-follow, six-step process. The cells can then be sprayed onto the wound and a new layer of healthy skin grows. It's approved in Europe... in the U.S., ReCell is essentially in phase 3, and we'll get data from that trial next year. Then Avita will file for approval, and ReCell should be on the U.S. market in 2015. From a burns and scalds standpoint, ReCell is going to dominate the market. From an acne scarring or vitiligo standpoint, I think it can capture significant market share."
Avita Medical Enrolls First Patients in ReCell(R) Trial for Chronic Leg Ulcers
Marketwire - Thu Aug 01, 8:30AM CDT
Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY)
Zacks Investment Research Initiates Coverage on Avita Medical (OTCQX:AVMXY) (ASX:AVH) with a Buy Recommendation - Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Wed Jun 26, 4:03PM CDT
Vancouver, British Columbia, June 26, 2013 - Zacks Investment Research has initiated coverage on Avita Medical (OTCQX:AVMXY) (ASX:AVH). Analyst Jason Napadano gives the company a buy rating and a $4.00 US price target, a premium of 95% over the $2.05 price the day the report was issued.
Avita Medical Analyst Coverage Initiated by Zacks
Marketwire - Wed Jun 19, 3:37PM CDT
Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) is pleased to announce that Zacks Investment Research, Inc (zacks.com), based in Chicago, IL, USA, has initiated coverage.
Granted Japanese Patent Expands Commercial Rights for ReCell(R) Spray-On Skin(R) Technology in Asia
Marketwire - Wed Apr 10, 8:30AM CDT
Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY) is pleased to announce that it has secured the grant of Japanese Patent No. 5214085 "Cell Suspension Preparation Technique and Device" by the Japanese Patent Office.
Avita Medical Skin Regeneration Symposium Attracts Top European Surgeons
Marketwire - Thu Mar 28, 8:30AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
M2 - Thu Feb 28, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/9qnbnv/global) has announced the addition of iCD Research's new report "Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry" to their offering. "Global Pharmaceutical Survey 2013-2014: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry is a new report that analyzes how pharmaceutical industry companies' media spend, marketing and sales strategies and practices, and business planning are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report provides the current size of the marketing and advertising budgets of global pharmaceutical industry suppliers and how spending by global pharmaceutical industry suppliers will change, providing an insight into global marketing behaviour. In addition, the report identifies future growt
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
M2 - Tue Feb 26, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/v5d4c7/global) has announced the addition of iCD Research's new report "Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" to their offering. Global Pharmaceutical Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry is a new report that analyzes how pharmaceutical industry companies' procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report gives access to category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procuremen
Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now
Marketwire - Thu Feb 14, 8:00AM CST
William Dolphin, Ph.D., the CEO of regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), was interviewed by SNNLive last week. Dr. Dolphin provides an update on Avita's flagship product, ReCell(R) Spray-On Skin(R). Based on Avita's proprietary technology, ReCell is designed to provide a rapid, safe and effective point of care treatment for regrowing skin tissue that has been damaged due to trauma, disease, or senescence.
Avita Medical Completes ISO Quality Audit, CE Mark Recertification
Marketwire - Wed Feb 13, 12:23PM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Avita Medical Appoints Dr. Michael S. Perry to Board of Directors
Marketwire - Wed Feb 06, 11:21AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
